XML 40 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity
 9 Months Ended
Sep. 30, 2022
Stockholders' Equity Note [Abstract]  
Equity Equity
Repurchase programs
On November 11, 2021, the Company announced that its Board of Directors authorized management to repurchase up to an aggregate of $250.0 million of Common Stock under a board-approved Share Repurchase Program, of which $187.9 million has been utilized to purchase 4.4 million shares as of September 30, 2022. During the three months ended September 30, 2022, there were no shares repurchased. During the nine months ended September 30, 2022, the Company has utilized $75.5 million to purchase 1.8 million shares. The Share Repurchase Program does not obligate the Company to acquire any specific number of shares. Repurchased shares will be available for use in connection with the Company's stock plans and for other corporate purposes.
Share-based compensation
During the nine months ended September 30, 2022, the Company granted stock options to purchase 0.7 million shares of common stock and 1.5 million restricted and performance stock units under the Emergent BioSolutions Inc. Stock Incentive Plan. Typically, the stock option and restricted stock unit grants vest over three equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end of the three-year performance period based on the Company's results compared to the performance criteria. Share-based compensation expense was recorded in the following financial statement line items:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Cost of product sales$1.8 $1.3 $5.4 $4.5 
Cost of CDMO0.4 0.3 1.4 0.8 
Research and development1.3 1.4 3.9 4.5 
Selling, general and administrative7.7 7.4 22.7 22.5 
Total share-based compensation expense$11.2 $10.4 $33.4 $32.3 
Accumulated other comprehensive loss, net of tax
The following table includes changes in accumulated other comprehensive loss, net of tax by component:
Defined Benefit Pension PlanDerivative InstrumentsForeign Currency Translation AdjustmentsTotal
Balance, December 31, 2021
$(4.0)$(4.5)$(7.6)$(16.1)
Other comprehensive income (loss) before reclassifications— 9.4 (0.4)9.0 
Amounts reclassified from accumulated other comprehensive loss— 1.9 — 1.9 
Net current period other comprehensive income (loss)— 11.3 (0.4)10.9 
Balance, September 30, 2022
$(4.0)$6.8 $(8.0)$(5.2)
Balance, June 30, 2022
$(4.0)$4.6 $(6.7)$(6.1)
Other comprehensive income (loss) before reclassifications— 2.6 (1.3)1.3 
Amounts reclassified from accumulated other comprehensive loss— (0.4)— (0.4)
Net current period other comprehensive income (loss)— 2.2 (1.3)0.9 
Balance, September 30, 2022
$(4.0)$6.8 $(8.0)$(5.2)
Balance, December 31, 2020
$(7.7)$(11.0)$(6.6)$(25.3)
Other comprehensive loss before reclassifications— (0.7)(1.4)(2.1)
Amounts reclassified from accumulated other comprehensive loss— 4.3 — 4.3 
Net current period other comprehensive income (loss)— 3.6 (1.4)2.2 
Balance, September 30, 2021
$(7.7)$(7.4)$(8.0)$(23.1)
Balance, June 30, 2021
$(7.7)$(6.4)$(8.3)$(22.4)
Other comprehensive income (loss) before reclassifications— (2.3)0.3 (2.0)
Amounts reclassified from accumulated other comprehensive loss— 1.3 — 1.3 
Net current period other comprehensive income (loss)— (1.0)0.3 (0.7)
Balance, September 30, 2021
$(7.7)$(7.4)$(8.0)$(23.1)
The tables below present the tax effects related to each component of other comprehensive income (loss):
Three Months Ended September 30,
20222021
PretaxTax ExpenseNet of taxPretaxTax ExpenseNet of tax
Derivative instruments$3.0 $(0.8)$2.2 $1.3 $(2.3)$(1.0)
Foreign currency translation adjustments0.1 (1.4)(1.3)0.3 — 0.3 
Total adjustments$3.1 $(2.2)$0.9 $1.6 $(2.3)$(0.7)
Nine Months Ended September 30,
20222021
PretaxTax ExpenseNet of taxPretaxTax ExpenseNet of tax
Derivative instruments$15.4 $(4.1)$11.3 $4.9 $(1.3)$3.6 
Foreign currency translation adjustments2.1 (2.5)(0.4)(1.4)— (1.4)
Total adjustments$17.5 $(6.6)$10.9 $3.5 $(1.3)$2.2